학술논문
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer
Document Type
Article
Author
Source
In: Prostate Cancer and Prostatic Diseases . (Prostate Cancer and Prostatic Diseases, December 2021, 24(4):1167-1180)
Subject
Language
English
ISSN
14765608
13657852
13657852